Launches

The Swedish company is celebrating approval for the first treatment for MCT8 deficiency

The Paris-headquartered group has been reflecting on a solid performance last year.

In recent US consumer health space rebranding, VEGA pays homage to celestial origins; AN Performance formulations launched with Chiquita co-branding; Crown simplifies Blue Lizard Australian Sunscreen portfolio with products tailored to life stages; and AMMD packaging shows a modern and elevated look.

Biocon Biologics’ management shared updates regarding their facilities, expansion, and fast upcoming ustekinumab biosimilar launch in the US. Also, Biocon made a final acquisition payment to Viatris, while increasing its stake in the biosimilars business.

McCaffrey Brands makes protein bar play; singer Meghan Trainor partners with Terra Origin on line extension; USANA’s new science chief has experience with Amway; Optimum Nutrition optimizes female athletes’ commitment; Kerry Group names commercial and North America chiefs; Cizzle Brands has advisors for launch; Tosi moves on from founders with Series B funding; and first PLT Health Solutions president not from founding family.

PCH announces 2.7 % reported growth to $290.3m in revenues for its latest quarter. Fleet line extensions don’t the brand against fiber product lines such as Metamucil and Benefiber. Licenses all markets for Hydralyte outside US. Two more Clear Eyes suppliers to be added as current pair repair their processes.

Boerner warned a year ago that BMS may see its revenue falter in the middle of this decade and the company’s 2025 guidance suggests that will happen this year after 2024 beat consensus.

Brands should “remain flexible and also explore ways to leverage this trend through innovation, consumer education and strategic retailer partnerships,” says Lauren Alexander of market research firm Emerson Group. “This is not a fad,” says Rick Polito of the Nutrition Business Journal.

Biocon reported another quarter of sluggish generics revenues but hopes that planned generic liraglutide launches and US facility expansion will grow this business segment.

Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.